# A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct04194775/  
OnCo record `nct04194775` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Lenvatinib in hepatocellular carcinoma, run by CStone Pharmaceuticals, active and no longer recruiting.

## Summary

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT04194775 by CStone Pharmaceuticals, with 534 participants enrolled, started 2019-12-13 and due to reach its primary completion in 2025-06-18. Interventions recorded: Nofazinlimab (CS1003)+Lenvatinib, Nofazinlimab (CS1003) Placebo+Lenvatinib. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04194775
- Phase: 3
- Setting: A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Sponsor: CStone Pharmaceuticals
- Enrolled: 534

## Sources

- ClinicalTrials.gov NCT04194775: https://clinicaltrials.gov/study/NCT04194775

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Lenvatinib](https://onco.cc/drugs/lenvatinib/)
- companies: [CStone Pharmaceuticals](https://onco.cc/companies/cstone/)

---
JSON: https://onco.cc/api/v1/entities/nct04194775.json